Home » Products » Src-bcr-Abl

Rous sarcoma oncogene/Breakpoint cluster region/Abl

Cat.No.	Product Name	Added

S1134	AT9283	Dec 2009
AT9283 is a small molecule a multi-targeted c-ABL, JAK2, Aurora A and B inhibitor with of 4, 1.2, 1.1 and approximate 3 nM for Bcr-Abl(T3151), Jak2 and Jak3, aurora A and B, respectively.

S1369	Bafetinib (INNO-406)	Jul 2010
Bafetinib (INNO-406) is an orally available, dual Abl/Lyn kinase inhibitor (cell IC50 : 11 ~ 22 nM).

S1014	Bosutinib (SKI-606)	Apr 2009
Src family kinase inhibitor. inhibited migration of breast cancer cell lines with IC50 values of 0.1 to 0.3 umol/L.

S1107	Danusertib (PHA-739358)	Aug 2009
Danusertib (PHA-739358) is a pyrrolo-pyrazole and small molecule Aurora kinases and Bcr-Abl kinase inhibitor with IC50 of 13, 79, and 61 nM for Aurora A, B, and C, respectively.

S1021	Dasatinib (BMS-354825)	Apr 2009
Dasatinib also known as BMS-354825, Sprycel, BMS354825 is ATP-competitive, dual SRC/ABL inhibitor. BMS-354825 inhibits all members of the Src family, including c-Src, Lck, Fyn, and Yes (IC50 < 1.1nmol/L).

S2634	DCC-2036	Jul 2011
DCC-2036 is an ABL switch control inhibitor with IC50 of 0.8 and 2 nM for u-ABL1native and p-ABL1native, respectively.

S5002	FTY720(Fingolimod)	Apr 2009
FTY720 Fingolimod Gilenia is Src-bcr-Abl Inhibitor & S1P receptor agonist with IC50 of 0.137, 10.98 nM for (S)- and (R)- FTY720-phosphate.

S2700	KX2-391	Oct 2011
KX2-391 is a synthetic, orally bioavailable small molecule and non-ATP competitive Src tyrosine kinase signaling inhibitor with an IC50 of average 72 nM.

S1033	Nilotinib (AMN-107)	Apr 2009
Inhibitor of BCR-ABL, IC50 < 30nM

S2202	NVP-BHG712	Mar 2011
NVP-BHG712 is a small molecule specific EphB4, VEGFR2, c-raf, c-src and c-Abl kinase inhibitor with ED50 of 25 nM, 4.2, 0.4, 1.3 and 1.7μM, respectively.

S2680	PCI-32765	Oct 2011
PCI-32765 is a high potent irreversible BTK inhibitor with an IC50 of 0.46 nM for the purified Btk.

S1490	Ponatinib (AP24534)	Sep 2010
Ponatinib (AP24534) is a novel potent, orally available small molecule multitargeted kinase inhibitor with IC50 of 0.37, 2, 1.5, 2.2, 1.1, 1and 0.24 nM for native pan-BCR-ABL, mutated form, VEGFR2, FGFR1, PDGFRα, mutant FLT3 phosphorylation and LYN.

S2622	PP121	Jun 2011
PP121 is a multitargeted dual receptor tyrosine kinases inhibitor with IC50 of 0.052, 1.4, 0.15, 1.1, 0.06, 0.01and 0.002 μM for p110α, p110β, p110δ, p110γ, DNA-PK, mTOR and PDGFR, respectively.

S2391	Quercetin(Sophoretin)	Feb 2011
Quercetin is a PI3K and PKC inhibitor with IC50 of 3.8 μM and 15µg/ml.

S1006	Saracatinib (AZD0530)	Apr 2009
Saracatinib (AZD0530) is a highly selective, orally available, dual-specific Src/Abl kinase inhibitor with IC50 of 2.7 and 30 nM for c-Src and Abl kinase, respectively.

S2243	WP1130	May 2011
WP1130 is a novel selective small molecular deubiquitinase (DUB) inhibitor and a Bcr/Abl destruction pathway activator with an IC50 of 1.8 μM for K562 cells.